✦ LIBER ✦

Treatment paradigms in the management of myeloproliferative disorders

✍ Scribed by Steven M Fruchtman

Book ID: 117821806
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 81 KB
Volume: 41
Category: Article
ISSN: 1532-8686
DOI: 10.1053/j.seminhematol.2004.02.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Current treatment paradigms in the manag

Current treatment paradigms in the management of soft tissue disorders

✍ Speed, Cathy 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 115 KB

Hydroxyurea Treatment of Myeloproliferat

Hydroxyurea Treatment of Myeloproliferative Disorders

✍ LÖFVENBERG, EVA ;NILSSON, TORBJÖRN ;WAHLIN, ANDERS ;JACOBSSON, LENNART 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 326 KB

Advances in the understanding and manage

Advances in the understanding and management of myeloproliferative disorders

✍ Radek Skoda 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Treatment of the myeloproliferative diso

Treatment of the myeloproliferative disorders with 32P

✍ Nathaniel I. Berlin 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 262 KB

New perspectives in the biology and trea

New perspectives in the biology and treatment of myeloproliferative disorders

📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 19 KB

New perspectives in managing myeloprolif

New perspectives in managing myeloproliferative disorders: focus on the patient

✍ Gunnar Birgegård 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

## Abstract Risk stratification is the basis for treatment decisions in the chronic myeloproliferative disorders, and in addition to the three established risk factors of previous thrombosis, age and platelets >1500 × 10^9^, cardiovascular risk factors should be addressed. In addition, premorbidity